Staff Reports
The Food and Drug Administration has quietly changed the Alzheimer’s landscape in a way more people will actually notice: patients can now start lecanemab treatment at home with a subcutaneous autoinjector. The branded starter dose, LEQEMBI IQLIK, is the new at‑home option that lets people begin therapy without the old ritual of hours in an infusion center. That’s big — and it deserves both a round of applause and a reality check.
What the FDA actually approved
The recent FDA decision cleared LEQEMBI IQLIK (lecanemab‑irmb) as an initiation dose for adults with early Alzheimer’s disease. Instead of forcing every patient to begin with intravenous infusions, physicians can now prescribe a once‑weekly subcutaneous regimen: a 500 mg starting dose delivered as two 250 mg injections. The companies behind the drug say patients may switch between IV and subcutaneous routes during treatment, and they expect wider availability soon. This approval builds on earlier trial data showing that the subcutaneous injections reach similar drug levels in the body and reduce amyloid plaque — the signature brain deposits linked to Alzheimer’s.
Safety still matters — don’t skip the fine print
ARIA, MRIs, and genetic risk
Let’s not let convenience become complacency. Lecanemab can cause amyloid‑related imaging abnormalities (ARIA), which include brain swelling and tiny bleeds. These events happen most often early in therapy and can be serious. The FDA and the LEQEMBI label make clear: patients need baseline and repeat MRI scans and close clinical follow‑up. Doctors are also urged to consider ApoE ε4 genetic testing because carriers — especially homozygotes — face higher ARIA risk. An autoinjector at home does not replace specialist oversight, MRI scheduling, or careful monitoring. If someone tweets “we’re reversing Alzheimer’s,” remind them that monitoring still costs money and brains don’t come with guarantees.
Access and cost — a real-world bottleneck
Yes, the autoinjector can help people who live far from infusion centers or who struggle with transportation. But the new route doesn’t erase the biggest barriers: price, MRI access, and payer rules. Manufacturer pricing examples put the weekly starter dose in the high hundreds, and add repeated MRIs and neurology visits and the bill keeps climbing. Medicare coverage remains governed by a national policy that ties payments to evidence collection, and private insurers vary widely. If taxpayers and patients are going to shoulder this, the federal government and insurers need to be clear about who pays, who qualifies, and how safety data get tracked.
We should cheer medical progress. A shot you can give at home that clears plaque is the kind of advance families have long hoped for. But cheerleading alone won’t protect seniors from rushed adoption, hidden costs, or rare but terrible side effects. Call this a cautious victory: more convenient access and a useful tool — provided regulators, doctors, insurers and drugmakers keep their eyes on safety, affordability, and honest claims. Progress is worth celebrating, but let’s do it with our feet on the ground and the MRI schedule in the calendar.
